Trial Profile

A Single and Repeat Dosing Study of the Safety, Drug Exposure and Clinical Activity of R-2487 in Patients With Rheumatoid Arthritis

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs R-2487 (Primary)
Indications Rheumatoid arthritis
Focus Adverse reactions
Sponsors Rise Therapeutics

Most Recent Events

23 Sep 2025 According to Rise Therapeutics media release, build on emerging clinical and biomarker data from Rise's ongoing clinical trial of R-2487 in RA; company plan to initiate Sjogren's Disease study.
04 Sep 2025 Protocol has been amended to include two new arms (Experimental: Six (6) week open label dose for Rheumatoid Arthritis patients and Experimental: Four (4) week open label dose for Rheumatoid Arthritis with Secondary Sjorgrens Syndrome patients) , it has been changed from 1 to 3.
04 Sep 2025 Planned number of patients changed from 36 to 73.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com